N-((1r,4r)-4-hydroxycyclohexyl)-3-phenethyl-1H-pyrazole-5-carboxamide

ID: ALA5288730

Max Phase: Preclinical

Molecular Formula: C18H23N3O2

Molecular Weight: 313.40

Names and Identifiers

Canonical SMILES:  O=C(N[C@H]1CC[C@H](O)CC1)c1cc(CCc2ccccc2)n[nH]1

Standard InChI:  InChI=1S/C18H23N3O2/c22-16-10-8-14(9-11-16)19-18(23)17-12-15(20-21-17)7-6-13-4-2-1-3-5-13/h1-5,12,14,16,22H,6-11H2,(H,19,23)(H,20,21)/t14-,16-

Standard InChI Key:  BXSLUWSVLHFSBS-KOMQPUFPSA-N

Molfile:  

 
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
    4.7069   -0.9634    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8819   -0.9634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4695   -1.6779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6445   -1.6779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2319   -0.9634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6444   -0.2489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4694   -0.2489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4069   -0.9634    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9945   -0.2489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4069    0.4654    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1695   -0.2489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2430   -0.9635    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0502   -0.7919    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1364    0.0286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3826    0.3642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8513    0.4413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5658    0.0288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2803    0.4413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9949    0.0289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7069    0.4408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7069    1.2661    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9968    1.6779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2803    1.2699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  3  2  1  0
  4  3  1  0
  5  4  1  0
  6  5  1  0
  7  6  1  0
  2  7  1  0
  5  8  1  6
  9  8  1  0
  9 10  2  0
 11  9  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 15 14  1  0
 15 11  2  0
 16 14  1  0
 16 17  1  0
 17 18  1  0
 19 18  2  0
 20 19  1  0
 21 20  2  0
 22 21  1  0
 23 22  2  0
 18 23  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5288730

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 313.40

Molecular Weight (Monoisotopic): 313.1790

AlogP: 2.23

#Rotatable Bonds: 5

Polar Surface Area: 78.01

Molecular Species: NEUTRAL

HBA: 3

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.64

CX Basic pKa: 2.45

CX LogP: 2.09

CX LogD: 2.09

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.79

Np Likeness Score: -0.94

References

1. Jo M, Koizumi K, Suzuki M, Kanayama D, Watanabe Y, Gouda H, Mori H, Mizuguchi M, Obita T, Nabeshima Y, Toyooka N, Okada T..  (2023)  Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.,  87  [PMID:37011768] [10.1016/j.bmcl.2023.129266]

Source

Source(1):

• Scientific Literature